enGene (NASDAQ:ENGN) vs. PharmaCyte Biotech (OTCMKTS:PMCBD) Head-To-Head Contrast

enGene (NASDAQ:ENGN) and PharmaCyte Biotech (OTCMKTS:PMCBD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, valuation, dividends and profitability.

Insider and Institutional Ownership

64.2% of enGene shares are owned by institutional investors. Comparatively, 0.0% of PharmaCyte Biotech shares are owned by institutional investors. 13.7% of enGene shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk & Volatility

enGene has a beta of -0.76, meaning that its stock price is 176% less volatile than the S&P 500. Comparatively, PharmaCyte Biotech has a beta of 0.27, meaning that its stock price is 73% less volatile than the S&P 500.

Profitability

This table compares enGene and PharmaCyte Biotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
enGene	N/A	-66.38%	-56.00%
PharmaCyte Biotech	N/A	-49.09%	-43.39%

Analyst Ratings

This is a breakdown of recent recommendations for enGene and PharmaCyte Biotech, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	0	0	8	1	3.11
PharmaCyte Biotech	0	0	0	0	0.00

enGene currently has a consensus target price of $31.43, indicating a potential upside of 265.45%. Given enGene’s stronger consensus rating and higher probable upside, equities analysts clearly believe enGene is more favorable than PharmaCyte Biotech.

Earnings and Valuation

This table compares enGene and PharmaCyte Biotech”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enGene	N/A	N/A	-$99.92 million	N/A	N/A
PharmaCyte Biotech	N/A	N/A	-$3.83 million	N/A	N/A

Summary

enGene beats PharmaCyte Biotech on 6 of the 10 factors compared between the two stocks.

About enGene

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

About PharmaCyte Biotech

PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Laguna Hills, CA.